Jpmorgan Chase & CO Adc Therapeutics Sa Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Jpmorgan Chase & CO holds 39,719 shares of ADCT stock, worth $139,413. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,719
Previous 37,021
7.29%
Holding current value
$139,413
Previous $73,000
23.29%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ADCT
# of Institutions
84Shares Held
53.9MCall Options Held
5KPut Options Held
7.6K-
Redmile Group, LLC San Francisco, CA15.7MShares$55 Million2.32% of portfolio
-
Prosight Management, LP Dallas, TX9.54MShares$33.5 Million4.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$20.9 Million0.26% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$12.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.02MShares$10.6 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $273M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...